


Abbreviated Accounts
for the Year Ended 31 December 2013
for
Aveo Pharma Limited

FRIDAY



A3H91SAA

A25

26/09/2014

#151

COMPANIES HOUSE

**Contents of the Abbreviated Accounts
for the Year Ended 31 December 2013**

	Page
Company information	1
Report of the independent auditors on the abbreviated accounts	2
Abbreviated balance sheet	3
Notes to the abbreviated accounts	4

Aveo Pharma Limited
Company Information
for the Year Ended 31 December 2013

Directors: T Ha-Ngoc

Secretary: Ovalsec Limited

Registered office: 2 Temple Back East
Temple Quay
Bristol
BS1 6EG

Registered number: 06456614 (England and Wales)

Auditors: The Norton Practice
Statutory Auditor
Highlands House
Basingstoke Road
Spencers Wood
Reading
Berkshire
RG7 1NT

**Report of the Independent Auditors to
Aveo Pharma Limited
Under Section 449 of the Companies Act 2006**

We have examined the abbreviated accounts set out on pages three to five, together with the full financial statements of Aveo Pharma Limited for the year ended 31 December 2013 prepared under Section 396 of the Companies Act 2006.

This report is made solely to the company, in accordance with Section 449 of the Companies Act 2006. Our work has been undertaken so that we might state to the company those matters we are required to state to it in a special auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors


The directors are responsible for preparing the abbreviated accounts in accordance with Section 444 of the Companies Act 2006. It is our responsibility to form an independent opinion as to whether the company is entitled to deliver abbreviated accounts to the Registrar of Companies and whether the abbreviated accounts have been properly prepared in accordance with the Regulations made under that Section and to report our opinion to you.

Basis of opinion

We conducted our work in accordance with Bulletin 2008/4 issued by the Auditing Practices Board. In accordance with that Bulletin we have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to deliver abbreviated accounts and that the abbreviated accounts to be delivered are properly prepared.

Opinion

In our opinion the company is entitled to deliver abbreviated accounts prepared in accordance with Section 444(3) of the Companies Act 2006, and the abbreviated accounts have been properly prepared in accordance with the Regulations made under that Section.



Anthony Campbell (Senior Statutory Auditor)
for and on behalf of The Norton Practice
Statutory Auditor
Highlands House
Basingstoke Road
Spencers Wood
Reading
Berkshire
RG7 1NT

Date: 28 September 2014


Aveo Pharma Limited (Registered number: 06456614)

Abbreviated Balance Sheet
31 December 2013

	Notes	2013 £	2012 £
Fixed assets			
Tangible assets	2	-	3,414
Current assets			
Debtors		95,291	151,382
Cash at bank		522,443	494,580
		<u>617,734</u>	<u>645,962</u>
Creditors			
Amounts falling due within one year		(3,182)	(1,112,487)
Net current assets/(liabilities)		<u>614,552</u>	<u>(466,525)</u>
Total assets less current liabilities		<u>614,552</u>	<u>(463,111)</u>
Capital and reserves			
Called up share capital	3	2	2
Capital contribution reserve		5,076,155	2,199,659
Profit and loss account		<u>(4,461,605)</u>	<u>(2,662,772)</u>
Shareholders' funds		<u>614,552</u>	<u>(463,111)</u>

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 9/23/14 and were signed on its behalf by:


T Ha-Ngoc - Director

The notes form part of these abbreviated accounts

**Notes to the Abbreviated Accounts
for the Year Ended 31 December 2013**

1. Accounting policies**Basis of preparing the financial statements**

The accounts have been prepared on a going concern basis, as the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company will continue to receive financial support from AVEO Pharmaceuticals, Inc. for a period not less than a year from the date of approval of the financial statements.

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

Tangible fixed assets

Tangible fixed assets are recorded at historical cost less accumulated depreciation. Cost comprises the purchase price and any costs directly attributable to bringing the asset to its working condition and location for its intended use. Depreciation is provided at the following annual rates in order to write down the cost of each asset to its estimated residual value over its estimated useful life:

Computer equipment 33.33% straight line

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Share based payments

Share options are granted by AVEO Pharmaceuticals Inc to employees of AVEO Pharma Limited. The value of options granted under the share based compensation plan have not been recorded in the financial statements as allowed by the Financial Reporting Standards for Smaller Entities (effective April 2008).

2. Tangible fixed assets

	Total £
Cost	
At 1 January 2013	4,293
Disposals	(4,293)
	<u> </u>
At 31 December 2013	-
	<u> </u>
Depreciation	
At 1 January 2013	879
Eliminated on disposal	(879)
	<u> </u>
At 31 December 2013	-
	<u> </u>
Net book value	
At 31 December 2013	-
	<u> </u>
At 31 December 2012	<u>3,414</u>

Notes to the Abbreviated Accounts - continued
for the Year Ended 31 December 2013

3. **Called up share capital**

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2013 £	2012 £
2	Ordinary	£1	<u>2</u>	<u>2</u>

4. **Ultimate parent company**

AVEO Pharmaceuticals, Inc. (incorporated in United States) is regarded by the directors as being the company's ultimate parent company.

The largest and smallest group of undertakings that accounts are drawn up for are that of AVEO Pharmaceuticals, Inc.